There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did
not persist in 2024. Tough refinancing conditions have been holding the market back, according to the German website.
But if an interest rate cut materializes over the summer, the outlook would look a lot b...
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the canc...
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress a...
The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of March 2024. This has already shown several promising effects in the preclinical phase and has been us...
UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a common feature of all cancer cells, holds the promise of a fundamentally new way of treating cancer a...